|Bid||5.11 x 2900|
|Ask||5.37 x 3200|
|Day's Range||5.16 - 5.41|
|52 Week Range||1.75 - 6.02|
|Beta (5Y Monthly)||1.94|
|PE Ratio (TTM)||65.75|
|Earnings Date||Apr 27, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||8.20|
Accuray Incorporated (NASDAQ: ARAY) announced today that the innovative ClearRT™ helical fan-beam kVCT imaging* capability has now been in clinical use for over two months, and is on track to expand into other markets. ClearRT on the Radixact® System is believed to have the potential to change the field of radiation oncology by enabling clinicians to easily, quickly and cost effectively acquire diagnostic-like quality CT images that enable them to "See More, Know More, and Do More," when treating tumors with radiation.
Accuray Incorporated (NASDAQ: ARAY) will report financial results for the third quarter of fiscal year 2021, ended March 31, 2021, after the market close on Tuesday April 27, 2021. Management will host a conference call to review the results at 1:30 p.m. PT / 4:30 p.m. ET on the same day.
The Zacks Analyst Blog Highlights: Smith & Nephew, Intuitive Surgical, Stryker Corp, Accuray and Medtronic